Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)

Randomized multicentre trial comparing two care organisations (ambulatory vs conventional inpatient) for patients undergoing transarterial chemoembolization (TACE) or radioembolization (TARE) for primary liver cancer (Hepato Cellular Carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCCA)). Patients are followed for 7 months to assess patient satisfaction, safety and clinical outcomes. A qualitative implementation study and a medico-economic evaluation (cost analysis and 5-years budget impact analysis) are embedded to assess acceptability, adoption, feasability, and sustainability and to inform scaling.

NCT Number	NCT06990659
Lead Sponsor	University Hospital, Angers Collaborators: Université Paris Cité
Conditions	Hepato Cellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma
Enrollment	206 participants
Start Date	2025-12-18
Primary Completion	2027-12-17 (estimated)
Study Completion	2028-12-17 (estimated)
Updated on ClinicalTrials.gov	2026-07-17